I. Introduction
CRISPR has emerged as a cornerstone of modern biotechnology, frequently cited across various fields—from genetic engineering and the treatment of hereditary diseases to the prevention of infectious illnesses and agricultural innovation. But what exactly is CRISPR that allows it to function as such a versatile tool? The answer lies in its ability to edit DNA with remarkable precision, from altering a single base pair to modifying entire genes. Given that all life is fundamentally built upon DNA, CRISPR’s capacity to intervene at this level positions it as a potentially paradigm-shifting technology for humanity.
Yet, as if governed by the law of equivalent exchange, the promise of revolutionary therapeutic advancement comes with serious costs—most notably, significant ethical and safety concerns. At its core, CRISPR treats the human genome as an editable object, which raises troubling questions about the boundaries of human dignity and life itself. This is especially true when CRISPR is applied to germline cells or embryos, where the intervention reaches beyond the individual and into future generations, triggering a cascade of philosophical dilemmas.
This raises a series of urgent questions: Is CRISPR truly an indispensable technology for human society? If it is merely supplementary, is it worth adopting despite its risks? Even if implemented, can it truly deliver on the outcomes it promises? If not, who should be held accountable—and how? And in the worst-case scenario, what kind of irreversible consequences might we face?
Answering these and other interrelated questions is essential if we are to adopt this technology in a way that is, at the very least, ethically tolerable and socially responsible.
CRISPR stands apart from earlier gene-editing technologies such as ZFNs and TALENs by offering greater simplicity and efficiency. With only a Cas9 protein and a single-guide RNA (sgRNA), it can accurately cleave specific DNA sequences and has shown remarkable adaptability across various cell types. These features have positioned CRISPR as a promising tool for treating genetic disorders like sickle cell anemia and cystic fibrosis at their root causes. While its early applications were limited to somatic cells, recent attempts to intervene at the germline or embryonic stages highlight the need for far more careful scrutiny. Though the benefits are real and tangible, the scope of its influence—spanning individual lives, future generations, and entire societies—demands deeper ethical reflection.
This paper aims to explore the fundamental ethical and philosophical concerns raised by the use of CRISPR technology. While not exhaustive, it seeks to assess whether a rational and morally sound justification for its use can be made. First, the mechanism by which CRISPR functions will be explained in detail. Second, the ethical and philosophical issues emerging from both its function and application will be analyzed. Third, the paper will investigate its potential societal impact through the lens of public sentiment and cultural psychology. Fourth, it will argue for the continued development and adoption of the technology by presenting justifiable examples. Finally, I will offer personal reflections and evaluations to conclude the discussion.
II. What is the CRISPR-Cas9?
The CRISPR-Cas9 system is a powerful gene-editing technology derived from a natural defense mechanism found in bacteria. Originally, bacteria developed this system to protect themselves from invading viruses and nucleic acids. When a virus attacks, the bacterial cell captures snippets of the viral DNA and stores them in its own genome within regions called CRISPR arrays. If the virus attacks again, the bacteria use these stored sequences to recognize the invader and send out a molecular “weapon”: the Cas9 protein guided by RNA.
The CRISPR requires two components to function
- Cas9 – an enzyme that acts like molecular scissors. It can cut DNA at specific locations. It is so-called endonuclease.
- Single-guide RNA (sgRNA) – crRNA (CRISPR RNA) + tracrRNA (trans-activating CRISPR RNA), which is a lab-created small fusion that tells Cas9 exactly where to cut by matching the target DNA sequence.
The system utilizes the Cas9 endonuclease, which is guided by a synthetic single-guide RNA (sgRNA) to a specific target sequence in the genome. Recognition of the target site requires the presence of a short Protospacer Adjacent Motif (PAM site), which enables Cas9 to bind and induce a Double-Strand Break (DSB) at the site. PAM site must present next to the target sequence like a marker, and it is indispensable.
Once a DSB is created, the cell activates endogenous DNA repair mechanisms, leading to one of two major outcomes. The first, there is Non-Homologous End Joining (NHEJ), which is an error-prone pathway that frequently results in insertions or deletions (indels), causing disruption of gene function—a process known as functional knock-out. The second, Homology-Directed Repair (HDR), utilizes an exogenous DNA template to introduce precise sequence changes, allowing for targeted gene knock-in. The presence or absence of a complementary DNA template determines which repair pathway is used, and affects the outcome of CRISPR editing-either a gene is destroyed, or it is edited precisely.
Modified Cas9 and Its Advanced Applications
Scientists can take advantage of this repair process to either disable a gene or insert a new sequence. This ability to precisely cut and modify genes makes CRISPR-Cas9 an invaluable tool for both scientific research and potential therapeutic applications.
While the WT Cas9 (wild-type Cas9) protein enables targeted genome cleavage via double-strand breaks (DSBs), advances in CRISPR-Cas9 technology have led to the development of various modified Cas9 variants, which expand the range of genomic manipulations far beyond simple gene disruption or insertion. These modified forms no longer serve solely as DNA scissors, but instead act as versatile molecular tools engineered for regulation, imaging, and precise editing.
1.Double-nickase Cas9
One such variant for minimizing off-target effects involves the use of double-nickase Cas9. In contrast to wild-type Cas9, which cleaves both strands of the DNA at once using a single enzyme guided by one gRNA, the double-nickase system employs two separate Cas9 nickase proteins, each engineered to cut only a single strand of DNA. These two nickases are directed to opposite strands at adjacent sites, such that a double-strand break is generated only when both nicks occur in close proximity.
2. Base editing
Base editors represent a transformative application of CRISPR-Cas9. By fusing dCas9 or nickase Cas9 to a deaminase, researchers can achieve site-specific single-nucleotide conversions (e.g., C-to-T or A-to-G) without inducing DSBs. This technique enables targeted correction of point mutations and is less likely to produce large-scale genomic rearrangements.
3. dCas9 (dead Cas9) with gRNA (full length)
Another extensively used modification is dead Cas9 (dCas9)—a catalytically inactive form that retains DNA-binding ability but lacks nuclease activity. When guided by a full-length gRNA, dCas9 can localize precisely to target sequences without inducing double-strand breaks. This feature has enabled a variety of functional applications. For example, when fused with transcriptional activators (such as VP64 or p300), dCas9 can enhance gene expression, while fusion with repressors (such as KRAB) allows for gene silencing. These approaches, collectively referred to as CRISPRa (activation) and CRISPRi (interference), are powerful tools for transcriptional modulation without altering the underlying DNA sequence. Osj8073 92966
Beyond gene regulation, dCas9 has also been employed in non-editing applications. Fusion with fluorescent proteins enables live-cell imaging of specific genomic loci, allowing researchers to visualize DNA dynamics in real time. Additionally, dCas9 fused with chromatin modifiers or epigenetic regulators has been used to investigate chromatin structure and function, offering insight into epigenetic landscapes and higher-order genome organization.
4. dgRNA (dead-guide RNA)
Furthermore, dead guide RNA (dgRNA), typically consisting of a shortened 14–15 nucleotide sequence with engineered MS2-binding loops, can recruit transcriptional machinery in the absence of cleavage activity. This RNA-based method of activation offers a unique advantage: transcription can be stimulated without the need for protein fusion domains or DNA cleavage, although repression is generally not feasible using this approach.
dCas9 fused with transcription factors directly carries the effector to the target site, functioning as a single unit for gene regulation—supporting both transcriptional activation and repression. In contrast, dgRNA relies on its own structural elements, such as MS2-binding loops, to recruit external activators without forming a protein, and is typically limited to transcriptional activation. While both systems operate without inducing DNA cleavage, their mechanisms differ: one delivers the effector, the other attracts it. In summary, they represent conceptually similar yet mechanistically distinct strategies for transcriptional regulation
5. CRISPR Screening
Finally, CRISPR-Cas9’s adaptability is further exemplified by its use in pooled high-throughput genetic screens, where large-scale gene function analyses can be performed efficiently. These tools have proven valuable in identifying therapeutic targets and dissecting complex biological pathways.
In summary, the development of modified Cas9 forms has fundamentally broadened the CRISPR toolkit—from cutting DNA to precisely controlling gene activity. Each variant serves a distinct function, tailored to specific experimental needs, and together they underscore the modularity and transformative potential of CRISPR-based technologies.
Compared with conventional gene-editing tools like Zinc-Finger Nucleases (ZFNs) or Transcription Activator-like Effector Nucleases (TALENs), CRISPR is faster, cheaper, easier to use, and more accurate. It is because it requires only the Cas9 enzyme and a short RNA sequence, rather than complex protein engineering.
Because of these strengths, CRISPR-Cas9 is now being used in a wide range of studies—from treating genetic diseases like sickle cell anemia, to modifying crops, to potentially preventing the spread of infectious diseases.
III. Applications in medicine and agriculture
CRISPR-Cas9 is transforming both medicine and agriculture with its precision and versatility.
In Medicine, CRISPR enables targeted gene modification that can treat or potentially cure a range of genetic disorders. Diseases like sickle-cell anemia, cystic fibrosis, Duchenne muscular dystrophy, and even certain cancers are already showing promising results in preclinical and clinical studies. Moreover, CRISPR contributes to immunotherapy, organoid development, and identification of drug targets in vivo. The ability to modify disease-related genes directly in human embryos or somatic cells opens new possibilities for long-term or even permanent cures. However, these applications also raise moral concerns, especially when applied to heritable human germline cells.
In Agriculture, CRISPR offers hope for addressing food insecurity and malnutrition. The technology can enhance crop yield, improve resistance to disease and pests, and boost nutritional content—such as increasing iron or vitamin A levels in staple foods. In regions where malnutrition remains a deadly issue, this represents a powerful intervention. Gene drive technology—another CRISPR-related application—could eradicate disease-carrying insects like malaria-transmitting mosquitoes, offering immense public health benefits. However, the ecological risks of such interventions, especially when gene drives could alter entire species, must not be underestimated.
These applications illustrate both the potential and the ethical complexity of CRISPR. It can alleviate human suffering on a massive scale, but the long-term impacts, especially unintended ones, require careful consideration and robust oversight.
